Research programme: Zika virus-like particle vaccine - GeoVax Labs

Drug Profile

Research programme: Zika virus-like particle vaccine - GeoVax Labs

Alternative Names: GOVX-ZM01

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator GeoVax Labs
  • Developer GeoVax Labs; University of Georgia
  • Class Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Zika virus infection

Most Recent Events

  • 11 Nov 2016 Preclinical trials in Zika virus infection (Prevention) in USA
  • 21 Jun 2016 GeoVax plans preclinical studies for Zika virus infection (Prevention) in USA
  • 16 Mar 2016 GeoVax collaborates with the University of Texas Medical Branch and Centre for Disease Control for the development of Zika virus vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top